Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock.
Tevogen Bio Trading Down 4.1%
TVGN stock traded down $0.06 during trading on Tuesday, hitting $1.29. The company had a trading volume of 1,596,534 shares, compared to its average volume of 5,030,952. Tevogen Bio has a 52-week low of $0.26 and a 52-week high of $3.09. The company has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $1.21.
Insider Buying and Selling
In other news, insider Neal Flomenberg sold 70,384 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56. Following the transaction, the insider now owns 3,898,828 shares of the company's stock, valued at approximately $4,249,722.52. This represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 406,510 shares of company stock valued at $446,763 over the last quarter. 73.24% of the stock is owned by corporate insiders.
Institutional Trading of Tevogen Bio
Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock valued at $465,000 after purchasing an additional 107,566 shares during the period. Northern Trust Corp boosted its stake in shares of Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after purchasing an additional 13,595 shares in the last quarter. Nuveen LLC bought a new position in shares of Tevogen Bio during the first quarter valued at approximately $97,000. XTX Topco Ltd purchased a new position in Tevogen Bio during the fourth quarter valued at approximately $55,000. Finally, Barclays PLC raised its stake in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after buying an additional 12,847 shares in the last quarter.
About Tevogen Bio
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Featured Stories
Before you consider Semper Paratus Acquisition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Semper Paratus Acquisition wasn't on the list.
While Semper Paratus Acquisition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
